MDL Panel Combines Suboxone Antitrust Cases In Pa.

Law360, New York (June 7, 2013, 3:37 PM EDT) -- Several putative antitrust class actions alleging Reckitt Benckiser Group PLC schemed to keep generics of its opiate addiction treatment Suboxone off the market were centralized Thursday in Pennsylvania federal court.

The U.S. Judicial Panel on Multidistrict Litigation consolidated in the U.S. District Court for the Eastern District of Pennsylvania a set of proposed class actions against Reckitt. The antitrust suits generally allege that Reckitt engaged in a “product-hopping” scheme, in which it promoted a film version of Suboxone over its older tablet form of the treatment...
To view the full article, register now.